DAZTA5-PPA2 Radiotracer for High-Contrast SSR2 Tumor Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PET/CT imaging agents for neuroendocrine tumors face challenges in achieving high sensitivity and specificity due to off-target uptake and suboptimal affinity for somatostatin receptor subtypes, leading to reduced image contrast and diagnostic accuracy.
Innovation Solution
Development of a radiopharmaceutical precursor DAZTA5-PPA2, which includes a novel chelator DAZTA5 and peptide ligand PPA2, allowing for rapid 68Ga labeling at ambient temperature and providing high affinity for somatostatin receptor 2 (SSR2) with reduced off-target uptake, enhancing image contrast and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If SSR agonist radiotracers are used to increase binding spectrum to encompass SSR3 and SSR5 in addition to SSR2, then tracer uptake in SSR positive target tissue is increased, but off-target uptake increases resulting in reduced tumour-to-background ratio and inferior image contrast
Solution Approach 1:
The patent applies local quality by designing the radiotracer to have differentiated binding characteristics: high affinity for SSR2 (target) versus selective lower affinity for off-target receptors. The specific molecular structure of the radiotracer is optimized to interact preferentially with SSR2, creating a localized binding preference that enhances target specificity while reducing off-target uptake.
Solution Approach 2:
The patent employs parameter changes by modifying the radiotracer's affinity parameters for different SSR subtypes. Through structural optimization and molecular design, the radiotracer achieves an optimal binding profile with high affinity for SSR2 while maintaining lower affinity for SSR3 and SSR5, thereby improving the tumour-to-background ratio without sacrificing target uptake.
2Stability of the object's composition
If radiolabeling is performed using conventional DOTA chelator, then stable complex formation is achieved, but labeling requires elevated temperature and extended time which is detrimental for heat-sensitive biomolecules
Solution Approach 1:
The patent applies parameter changes by transitioning from conventional DOTA chelator to a novel chelator system that enables radiolabeling at ambient temperature. The new chelator maintains stable complex formation with Gallium-68 while eliminating the need for elevated temperature processing, thereby preserving the integrity of heat-sensitive peptide ligands and reducing degradation during the labeling process.
3Stability of the object's composition
If radiolabeling is performed using conventional DOTA chelator, then stable complex formation is achieved, but extended cooling time is required before injection which is incompatible with the short half-life of Ga-68
Solution Approach 1:
The patent applies preliminary action by pre-optimizing the chelator-radiometal complex formation kinetics. The novel chelator system is designed to achieve rapid, quantitative complexation with Gallium-68 at ambient temperature, eliminating the need for extended cooling periods. This allows the radiopharmaceutical to be prepared and injected within the optimal time window of the Ga-68 half-life, maximizing radioactive decay efficiency and image quality.
4Quantity of substance
If SSR antagonist radiotracers are used to address inactive receptor forms, then uptake in preclinical and clinical settings is increased, but affinity for active receptors may be reduced affecting diagnostic sensitivity
Solution Approach 1:
The patent applies parameter changes by optimizing the radiotracer's binding characteristics to achieve a balance between antagonist and agonist properties. The molecular structure is fine-tuned to maintain high affinity for SSR2 while enabling effective binding to both active and inactive receptor forms. This optimization ensures high diagnostic sensitivity without sacrificing the benefits of increased target uptake achieved through antagonist mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DAZTA5-PPA2-based radiotracers exhibit exceptional target-to-background ratios, enabling high sensitivity and selectivity for tumor lesions with low uptake in healthy tissues, improving diagnostic accuracy and therapeutic efficacy for neuroendocrine cancers.
Implementation Method 1
a precursor designated as DAZTA5-PPA2 or a salt thereof for radiolabeling and targeting of somatostatin receptor 2 (SSR2) comprising the chelator DAZTA5
Implementation Method 2
Positron Emission Tomography (PET) combined with Computed Tomography (CT) using Gallium-68 (Ga-68 or 68Ga)
Data Source
AI summary
A precursor designated as DAZTA5-PPA2 for PET/CT diagnosis and nuclear therapy|of SSR active lesions with radioisotopes 68Ga and 177Lu provides improved|affinity, specificity and imaging of small metastases.